In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality.

Journal Article (Journal Article)

Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021;10:CD013650. 34693515.

Full Text

Duke Authors

Cited Authors

  • Kelsey, MD; Newby, LK

Published Date

  • March 2022

Published In

Volume / Issue

  • 175 / 3

Start / End Page

  • JC26 -

PubMed ID

  • 35226528

Electronic International Standard Serial Number (EISSN)

  • 1539-3704

Digital Object Identifier (DOI)

  • 10.7326/J22-0003


  • eng

Conference Location

  • United States